logo-loader
viewCytoDyn

Full interview: CytoDyn looks to FDA to green light Phase 2 trials of leronlimab to treat colon cancer

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech has filed a Phase 2 protocol with the Food and Drug Administration for a combination therapy of leronlimab and regorafenib to treat patients with metastatic colorectal cancer.

Dr Pourhassan explains that the Vancouver, Washington-based biotechnology company's animal studies with this indication show "strong results" so there is no reason why CytoDyn should not progress to Phase 2 trials.

Quick facts: CytoDyn

Price: 0.341 USD

OTCMKTS:CYDY
Market: OTCMKTS
Market Cap: $132.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn CEO says firm can be one of the top biotech...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech has dosed its first patient with metastatic triple-negative breast cancer using its flagship drug leronlimab, adding company has the chance of being one of the top biotech companies in the world, pending clinical...

6 days, 20 hours ago

2 min read